166374-49-8 Usage
Description
(1S,2R,3S,4S,6S)-8-[3-Oxatricyclo[3.2.1.0(2,4)]oct-6-yl]-1,3-dipropylxanthine is a complex xanthine derivative and a purine alkaloid that functions as a potent and selective antagonist of adenosine receptors. (1S,2R,3S,4S,6S)-8-[3-Oxatricyclo[3.2.1.0(2,4)]oct-6-yl]-1,3-dipropylxanthine has garnered attention for its potential pharmaceutical applications, particularly in the treatment of neurological and cardiovascular disorders, due to its high affinity for the A1 and A2A adenosine receptors.
Uses
Used in Pharmaceutical Industry:
(1S,2R,3S,4S,6S)-8-[3-Oxatricyclo[3.2.1.0(2,4)]oct-6-yl]-1,3-dipropylxanthine is used as a therapeutic agent for the treatment of neurological and cardiovascular disorders. Its high affinity for adenosine receptors A1 and A2A makes it a promising candidate for the development of novel treatments targeting these conditions.
Used in Organic Chemistry Research:
In the field of organic chemistry, (1S,2R,3S,4S,6S)-8-[3-Oxatricyclo[3.2.1.0(2,4)]oct-6-yl]-1,3-dipropylxanthine is used as a subject of study for the synthesis of related compounds with improved pharmacological profiles. Its structural complexity and unique properties have attracted researchers interested in enhancing its therapeutic potential and exploring its applications in medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 166374-49-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,6,3,7 and 4 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 166374-49:
(8*1)+(7*6)+(6*6)+(5*3)+(4*7)+(3*4)+(2*4)+(1*9)=158
158 % 10 = 8
So 166374-49-8 is a valid CAS Registry Number.
166374-49-8Relevant articles and documents
Synthesis of an o-nitrobenzyl attached A1 adenosine receptor antagonist, a prodrug approach
Chang, HeXi,Ensinger, Carol,McCargar, Robert D.,Vittimberga, Bruno M.
, p. 2605 - 2611 (2007/10/03)
The o-nitrobenzyl group, possessing distinct advantage of being photolabile under mild conditions, was successfully connected to 8-(5,6-epoxynorbornan-2-yl)-1,3-dipropylxanthine (5), a high specific A1 adenosine receptor antagonist. The resulting compound 4 would have potential use as a prodrug.
